Table of Contents
Table of Contents 3
List of Tables 5
List of Figures 5
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Abzena Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Abzena Plc, Medical Devices Deals, 2012 to YTD 2018 11
Abzena Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Abzena Plc, Pharmaceuticals & Healthcare, Deal Details 14
Venture Financing 14
Abzena Raises Funds through Venture Financing 14
Partnerships 16
Abzena Enters into Agreement with Enleofen Bio 16
Abzena Partners with UGA Biopharma 17
Abzena and Baylor Scott & White Research Institute Form Joint Venture 18
Abzena Enters into Agreement with Apitope 19
Antitope Extends Research Agreement with ANRS, INSERM and Baylor Research Institute 20
PolyTherics Enters into Agreement with Alpha Cancer to Produce Tumor Targeting Drug Conjugate Pact 21
Antitope Enters Into Research Agreement With Annexon For Therapeutic Antibodies 22
Tube Pharma Enters into Co-Development Agreement with PolyTherics for Antibody Drug Conjugates 23
Antitope Enters Into Research Agreement With ChemomAb For Composite Human Antibodies 24
Antitope Enters Into Co-Development Agreement With Research Corporation Technologies For Therapeutic Protein 25
Antitope Enters Into Co-Development Agreement With Eden Biodesign For Therapeutic Antibodies 26
Antitope Enters Into Research Agreement With NeuroPhage Pharma 27
Biotecnol Enters Into Co-Development Agreement With PolyTherics For Tribody Drug Conjugates 28
PolyTherics Enters Into Co-Development Agreement With Spirogen For Cancer Drug 29
Licensing Agreements 30
Tmunity Therapeutics Enters into Licensing Agreement with Abzena 30
Telix Pharma Enters into Licensing Agreement with Abzena 31
OBI Pharma Enters into Licensing Agreement with Abzena 32
Abzena Enters into Licensing Agreement for ThioBridge 33
Trieza Therapeutics Enters into Licensing Agreement with Abzena 34
ProtAb Enters into License Agreement with Antitope 35
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Factor IX 36
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Factor VIIa 37
Antitope Enters into Licensing Agreement with University College London for Humanized Antibodies 38
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Technology 39
Equity Offering 40
Abzena Raises USD31 Million in Private Placement of Shares 40
Abzena Raises Funds through Private Placement of Shares upon Exercise of Warrants 41
Abzena Raises USD31.8 Million in Private Placement of Shares 42
Abzena Completes IPO 43
Acquisition 44
Astro Bidco to Acquire Abzena 44
Abzena Acquires The Chemistry Research Solution for USD15 Million 46
Abzena Acquires PacificGMP 47
PolyTherics Acquires Antitope For US$20.7 Million 49
Abzena Plc – Key Competitors 50
Abzena Plc – Key Employees 51
Abzena Plc – Locations And Subsidiaries 52
Head Office 52
Other Locations & Subsidiaries 52
Joint Venture 53
Recent Developments 54
Strategy And Business Planning 54
Jan 05, 2018: Abzena Takes on New Facilities in Cambridge, UK and San Diego 54
Financial Announcements 55
Apr 16, 2018: Abzena: Pre-Close Period Trading Update FY2018 55
Dec 12, 2017: Half year results: Growth strategy progressing 57
Jun 13, 2017: Abzena Announces Full year results: integration and growth seen across the Group, with 41% underlying increase in revenues 58
Feb 21, 2017: Abzena: Trading and business update 59
Corporate Communications 61
Oct 16, 2018: Abzena announces the appointment of Jonathan Goldman, MD as Chief Executive Officer 61
Legal and Regulatory 62
Mar 05, 2018: Abzena: Settlement of claim 62
Government and Public Interest 63
Mar 02, 2017: Abzena, UCL secure £3.5m grant from MRC for autoimmune therapy research 63
Product News 64
Mar 06, 2017: ‘Abzena inside’ product for neurodegenerative conditions moves into Phase II trial 64
Other Significant Developments 65
Mar 26, 2018: Facility Remodelling Completed for Abzena’s New Antibody-Drug Conjugate GMP Manufacturing Suite 65
Nov 14, 2017: Novel Antibodies against a Ground-Breaking New Target for the Treatment of Cardiovascular Fibrosis Developed by Enleofen Bio, with Support from Abzena, Featured in ‘Nature’ Article 66
Appendix 67
Methodology 67
About GlobalData 67
Contact Us 67
Disclaimer 67
Abzena Plc, Pharmaceuticals & Healthcare, Key Facts, 2018 2
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Abzena Plc, Pharmaceuticals & Healthcare Deals By Type, 2012 to YTD 2018 8
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Abzena Plc, Deals By Therapy Area, 2012 to YTD 2018 10
Abzena Plc, Medical Devices Deals, 2012 to YTD 2018 11
Abzena Plc, Pharmaceuticals & Healthcare, Deals Summary, 2012 to YTD 2018 12
Abzena Raises Funds through Venture Financing 14
Abzena Enters into Agreement with Enleofen Bio 16
Abzena Partners with UGA Biopharma 17
Abzena and Baylor Scott & White Research Institute Form Joint Venture 18
Abzena Enters into Agreement with Apitope 19
Antitope Extends Research Agreement with ANRS, INSERM and Baylor Research Institute 20
PolyTherics Enters into Agreement with Alpha Cancer to Produce Tumor Targeting Drug Conjugate Pact 21
Antitope Enters Into Research Agreement With Annexon For Therapeutic Antibodies 22
Tube Pharma Enters into Co-Development Agreement with PolyTherics for Antibody Drug Conjugates 23
Antitope Enters Into Research Agreement With ChemomAb For Composite Human Antibodies 24
Antitope Enters Into Co-Development Agreement With Research Corporation Technologies For Therapeutic Protein 25
Antitope Enters Into Co-Development Agreement With Eden Biodesign For Therapeutic Antibodies 26
Antitope Enters Into Research Agreement With NeuroPhage Pharma 27
Biotecnol Enters Into Co-Development Agreement With PolyTherics For Tribody Drug Conjugates 28
PolyTherics Enters Into Co-Development Agreement With Spirogen For Cancer Drug 29
Tmunity Therapeutics Enters into Licensing Agreement with Abzena 30
Telix Pharma Enters into Licensing Agreement with Abzena 31
OBI Pharma Enters into Licensing Agreement with Abzena 32
Abzena Enters into Licensing Agreement for ThioBridge 33
Trieza Therapeutics Enters into Licensing Agreement with Abzena 34
ProtAb Enters into License Agreement with Antitope 35
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Factor IX 36
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Factor VIIa 37
Antitope Enters into Licensing Agreement with University College London for Humanized Antibodies 38
PolyTherics Enters Into Licensing Agreement With Pro Bono Bio Group For TheraPEG Technology 39
Abzena Raises USD31 Million in Private Placement of Shares 40
Abzena Raises Funds through Private Placement of Shares upon Exercise of Warrants 41
Abzena Raises USD31.8 Million in Private Placement of Shares 42
Abzena Completes IPO 43
Astro Bidco to Acquire Abzena 44
Abzena Acquires The Chemistry Research Solution for USD15 Million 46
Abzena Acquires PacificGMP 47
PolyTherics Acquires Antitope For US$20.7 Million 49
Abzena Plc, Key Competitors 50
Abzena Plc, Key Employees 51
Abzena Plc, Other Locations 52
Abzena Plc, Subsidiaries 52
Abzena Plc, Joint Venture 53
List of Figures
Abzena Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 2
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 2
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 2
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 2
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Year, 2012 to YTD 2018 7
Abzena Plc, Pharmaceuticals & Healthcare, Deals by Type, 2012 to YTD 2018 8
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Region, 2012 to YTD 2018 9
Abzena Plc, Pharmaceuticals & Healthcare, Deals By Therapy Area, 2012 to YTD 2018 10
Abzena Plc, Medical Devices Deals, 2012 to YTD 2018 11